Skip to main content

Greenberg Traurig Represents SciVac Therapeutics in Agreement to Acquire VBI Vaccines

MIAMI Nov. 5, 2015 – International law firm Greenberg Traurig, P.A. recently represented SciVac Therapeutics Inc. (TSX:VAC)(OTCQX:SVACF) in its agreement to acquire VBI Vaccines Inc. (NASDAQ:VBIV). Upon consummation of the acquisition, the combined, commercial-stage company will have both a licensed hepatitis B ("HBV") vaccine and a pipeline of preventative and therapeutic vaccine candidates.

Following the acquisition, Greenberg Traurig’s longtime client OPKO Health, Inc. will be the largest shareholder of the combined company. OPKO is a multinational biopharmaceutical and diagnostics company, led by Chairman and Chief Executive Officer Dr. Phillip Frost.

The Greenberg Traurig deal team was led by Miami Corporate & Securities Shareholders Robert L. Grossman and Drew M. AltmanGrossman also serves as also Co-Chair of the firm’s Israel Practice. Other deal team members include:

  • Indira Sordo, Miami, Corporate & Securities

  • Samantha D. Glover, Miami, Corporate & Securities

  • Michael R. Einig, Miami, Tax

  • Seth J. Entin, Miami, Tax

  • Barry J. Schindler, New Jersey, Intellectual Property & Technology

  • Elysa B. Goldberg, New Jersey, Intellectual Property & Technology

  • Luis Fernandez De La Vara, Miami, Corporate & Securities

SciVac Therapeutics Inc., headquartered in Rehovot Israel, is in the business of developing, producing and marketing biological products for human healthcare. SciVac's flagship product, Sci-B-Vac™, is a recombinant third-generation hepatitis B vaccine. SciVac also offers contract development and manufacturing services to the life sciences and biotechnology markets.